Jay Short
![publicity photo in suit](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a5/Jay_Short.jpeg/220px-Jay_Short.jpeg)
Jay M. Short is founder and CEO of the antibody drug company BioAtla, LLC.[1] He was vice president of research and operations at Stratagene (now Agilent Technologies), president of the Stratagene antibody subsidiary Stratacyte, then founder and CEO of Diversa until 2005.[2] While at Diversa, Short invented methods of protein and pathway discovery via metagenomics, in addition to evolution technologies gene site saturation mutagenesis (GSSM) and GeneReassembly,[3] and was the first to combine these discovery and evolution technologies.
On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's conditionally-active biologics (CAB) antibody platform and Pfizer's antibody-drug conjugate (ADC) payloads.[4] BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone commitments as well as tiered marginal royalties reaching double digits on potential future product sales.[5]
Short is also founder of the E. O. Wilson Biodiversity Foundation,[6] chairman of the board of Ciris Energy,[7] and member of the board of directors of Senomyx.[8] Short received his Ph.D. in biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in chemistry from Taylor University in Upland, Indiana.
References
[edit]- ^ "PROFILE: Diversity in vision and expertise: Jay Short promotes sustainable bioscience". Industrial Biotechnology. 3 (1): 13–18. 1 March 2007. doi:10.1089/ind.2007.3.013.
- ^ Somers, Terri (October 7, 2005). "Diversa CEO resigns from biotech". The San Diego Union-Tribune. Retrieved 12 August 2011.
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 2016-03-04. Retrieved 2015-12-15.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ "BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics". PR Newswire. 7 December 2015. Retrieved 9 December 2015.
- ^ "ADCs take CAB ride to tumor-town: $1B deal with Pfizer sets Bioatla on development road". BioWorld. 8 December 2015. Retrieved 9 December 2015.
- ^ "Foundation History". Web site.
- ^ "An alternative to fracking?". San Diego Union-Tribune. 24 February 2013.
- ^ "Jay M. Short, Ph.D. Joins the Board of Directors of Senomyx, Inc". PR Newswire. 13 April 2004. Retrieved 11 May 2016.